Janux Therapeutics Inc. (NASDAQ:JANX) said it will discontinue development of its EGFR-targeted JANX008 program after internal analysis showed the therapy did not meet the company's threshold for continued investment, despite some durable responses in patients.
Program Review Leads To Strategic Shift
The clinical-stage biotech reached the decision following completion of the Phase 1a portion of its study, which evaluated JANX008 across multiple solid tumor types. The trial included both dose escalation and expansion cohorts.
After reviewing the dataset against predefined criteria, the company concluded that while certain patients experienced sustained responses, the overall depth and consistency of efficacy were insufficient relative to other pipeline opportunities. As a result, Janux opted to reallocate resources toward programs with stronger potential.
The company emphasized that the move is limited to JANX008 and does not alter its broader TRACTr platform strategy.
Safety Profile Offers Platform Insights
Despite discontinuing the program, Janux highlighted several findings that could inform future development efforts. Cytokine release syndrome was reported infrequently and was largely confined to mild cases, enabling approval for outpatient dosing.
JANX008 also demonstrated a differentiated tolerability profile compared to conventional EGFR-targeted therapies, with fewer gastrointestinal, dermatologic, and subcutaneous adverse events typically associated with such treatments.
However, musculoskeletal toxicities emerged as dose-limiting, underscoring constraints tied to the EGFR target itself.
Still, the company noted that its TRACTr approach enabled dosing flexibility sufficient to evaluate activity across a range of exposure levels.
Leadership Emphasizes Discipline
“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, president and CEO of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”
“The JANX008 study enabled a rigorous evaluation of activity for this EGFR-targeted TRACTr construct,” said William Go, chief medical officer of Janux. “We observed objective responses and disease control across treated patients. These findings provide important insight into how target biology and masking strategy define the therapeutic window and inform the continued advancement of our pipeline.”
Analyst Calls Prudent Update
William Blair on Tuesday wrote, “While we had held out some hope for potential upside from JANX008 updates, it was clearly not a focus for investors given there has been relatively limited public disclosure of data from the program, and ultimately if the efficacy was not meeting internal hurdles then it is prudent to discontinue the program.”
JANX Stock Price Activity: Janux Therapeutics shares were down 1.51% at $15.00 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Photo: Shutterstock
Login to comment